Holen Sie sich die Stockscreener-App
11.40
7.55%
0.80
Handel nachbörslich:
11.40
Schlusskurs vom Vortag:
$10.60
Offen:
$10.55
24-Stunden-Volumen:
750.44K
Relative Volume:
0.76
Marktkapitalisierung:
$458.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+6.24%
1M Leistung:
+14.80%
6M Leistung:
-46.60%
1J Leistung:
+0.00%
1-Tages-Spanne:
$10.48
$11.41
1-Wochen-Bereich:
$10.26
$11.41
52-Wochen-Spanne:
$4.17
$28.99
Septerna Inc Stock (SEPN) Company Profile
Firmenname
Septerna Inc
Sektor
Branche
Telefon
650-338-3533
Adresse
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Vergleichen Sie SEPN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
11.40 | 458.06M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-11-19 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-19 | Eingeleitet | TD Cowen | Buy |
| 2024-11-19 | Eingeleitet | Wells Fargo | Overweight |
Septerna Inc Aktie (SEPN) Neueste Nachrichten
Septerna, Inc. Holds Virtual Annual Stockholders Meeting - TipRanks
Driehaus Capital Management LLC Increases Stake in Septerna Inc - GuruFocus
Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies - MSN
Nuveen Asset Management LLC Buys New Stake in Septerna, Inc. (NASDAQ:SEPN) - Defense World
Bank of America Corp DE Makes New Investment in Septerna, Inc. (NASDAQ:SEPN) - Defense World
Kalkine: Septerna Inc Gains Traction on NASDAQ 100 Index from Kalkine - Kalkine Media
Septerna To Present At Jefferies Conference; SEP-631 Phase 1 Trial On Track For Q3 - Nasdaq
Deutsche Bank AG Invests $239,000 in Septerna, Inc. (NASDAQ:SEPN) - Defense World
Septerna to Present at Jefferies Global Healthcare Conference - The Manila Times
GPCR Pioneer Septerna Reveals Latest Drug Discovery Progress at Major Jefferies Healthcare Event - Stock Titan
Jane Street Group LLC Invests $600,000 in Septerna, Inc. (NASDAQ:SEPN) - Defense World
Analysts Think These Stocks Could More Than Double in Value - Investing.com
Analysts Think These Stocks Could More Than Double in Value - MarketBeat
Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect? - MSN
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna - MSN
Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled - MSN
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer - The Globe and Mail
Novo Nordisk, Septerna Agree $2.2 Billion Obesity Pill Deal - MSN
Cantor Fitzgerald Remains a Buy on Septerna, Inc. (SEPN) - The Globe and Mail
Wells Fargo & Company Boosts Septerna (NASDAQ:SEPN) Price Target to $18.00 - Defense World
Septerna First Quarter 2025 Earnings: US$0.49 loss per share (vs US$6.35 loss in 1Q 2024) - simplywall.st
22,095 Shares in Septerna, Inc. (NASDAQ:SEPN) Bought by The Manufacturers Life Insurance Company - Defense World
ETFs to Capitalize on the Novo Nordisk-Septerna Deal - MSN
Novo Nordisk in pact with Septerna for oral obesity drugs - MSN
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments - MSN
Septerna: Novo's Investment In Incretin Program IntriguesOne For The Watchlist - Seeking Alpha
Where Septerna Stands With Analysts - Benzinga
Septerna: Deal With Novo Nordisk Is A Game Changer, While It Still Trades Well Below Net Cash - Seeking Alpha
Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight By Investing.com - Investing.com Nigeria
Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight - Investing.com
Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership - PMLiVE
Septerna price target raised to $18 from $11 at Wells Fargo - TipRanks
Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills - MSN
Biotech Stocks Worth Watching – May 14th - Defense World
Novo Nordisk (NVO) Deal Highlights Strategic Potential Amid Septerna Developments | NVO Stock News - GuruFocus
Septerna, Inc.: Strategic Partnerships and Promising Pipeline Drive Buy Rating - TipRanks
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna - MSN
Septerna reports Q1 EPS (49c), consensus (45c) - TipRanks
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results - The Manila Times
Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs - Contract Pharma
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk - MSN
Novo Nordisk Inks $2.2 Billion Deal with Septerna to Advance Obesity and Diabetes Treatments - MSN
Novo Nordisk, Septerna collaborate on developing GPCR therapies - World Pharmaceutical Frontiers
Novo Nordisk Partners with Septerna for New Obesity Drug Development - GuruFocus
Novo Nordisk, Septerna Ink Up To $2.2B Obesity Drug Deal - Law360
Novo Nordisk Looks To Septerna For Oral Obesity Options - insights.citeline.com
Septerna joins a $2.2B obesity deal with Novo - BioWorld MedTech
Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing - Investor's Business Daily
Finanzdaten der Septerna Inc-Aktie (SEPN)
Es liegen keine Finanzdaten für Septerna Inc (SEPN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Septerna Inc-Aktie (SEPN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Finer Jeffrey | CEO and President |
Apr 03 '25 |
Option Exercise |
2.76 |
5,000 |
13,800 |
826,907 |
| Ezekowitz Alan | Director |
Mar 07 '25 |
Buy |
6.93 |
13,319 |
92,270 |
117,420 |
| Ezekowitz Alan | Director |
Mar 06 '25 |
Buy |
6.00 |
41,355 |
248,130 |
104,101 |
| Ezekowitz Alan | Director |
Mar 05 '25 |
Buy |
5.82 |
37,835 |
220,260 |
62,746 |
| Ezekowitz Alan | Director |
Mar 04 '25 |
Buy |
6.35 |
7,491 |
47,544 |
24,911 |
| Finer Jeffrey | CEO and President |
Feb 25 '25 |
Buy |
5.68 |
10,000 |
56,765 |
764,907 |
| Finer Jeffrey | CEO and President |
Feb 26 '25 |
Buy |
5.70 |
4,000 |
22,796 |
768,907 |
| Finer Jeffrey | CEO and President |
Feb 27 '25 |
Buy |
5.80 |
3,000 |
17,400 |
771,907 |
| Labrucherie Gil M | Chief Financial Officer |
Feb 25 '25 |
Buy |
5.59 |
6,282 |
35,116 |
36,282 |
| Labrucherie Gil M | Chief Financial Officer |
Feb 27 '25 |
Buy |
5.85 |
3,718 |
21,750 |
40,000 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):